127 related articles for article (PubMed ID: 34413947)
1. Targeting the KRAS G12D Mutant as Potential Therapy in Cancer.
Kargbo RB
ACS Med Chem Lett; 2021 Aug; 12(8):1212-1213. PubMed ID: 34413947
[No Abstract] [Full Text] [Related]
2. Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant-Novel Insights from Computer-Aided Drug Discovery.
Ramalingam PS; Balakrishnan P; Rajendran S; Jothi A; Ramalingam R; Arumugam S
Curr Issues Mol Biol; 2023 Mar; 45(3):2136-2156. PubMed ID: 36975507
[TBL] [Abstract][Full Text] [Related]
3. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with
Drilon A; Schoenfeld AJ; Arbour KC; Litvak A; Ni A; Montecalvo J; Yu HA; Panora E; Ahn L; Kennedy M; Haughney-Siller A; Miller V; Ginsberg M; Ladanyi M; Arcila M; Rekhtman N; Kris MG; Riely GJ
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936194
[No Abstract] [Full Text] [Related]
4. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of purine and pyrimidine-based
Park SY; Gowda Saralamma VV; Nale SD; Kim CJ; Jo YS; Baig MH; Cho J
Heliyon; 2024 Apr; 10(7):e28495. PubMed ID: 38617914
[TBL] [Abstract][Full Text] [Related]
7. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
8. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura SF; Khan HY; Azmi AS
Front Oncol; 2022; 12():1013902. PubMed ID: 36531078
[TBL] [Abstract][Full Text] [Related]
9. Exosomal miR-3131 derived from endothelial cells with KRAS mutation promotes EndMT by targeting PICK1 in brain arteriovenous malformations.
He Q; Huo R; Wang J; Xu H; Zhao S; Zhang J; Sun Y; Jiao Y; Weng J; Zhao J; Cao Y
CNS Neurosci Ther; 2023 May; 29(5):1312-1324. PubMed ID: 36718590
[TBL] [Abstract][Full Text] [Related]
10. Targeting the "Undruggable" Driver Protein, KRAS
Kargbo RB
ACS Med Chem Lett; 2023 Apr; 14(4):365-366. PubMed ID: 37077403
[TBL] [Abstract][Full Text] [Related]
11. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
Kerr EM; Gaude E; Turrell FK; Frezza C; Martins CP
Nature; 2016 Mar; 531(7592):110-3. PubMed ID: 26909577
[TBL] [Abstract][Full Text] [Related]
12. Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
[TBL] [Abstract][Full Text] [Related]
13. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
14. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic high affinity T cell receptor targeting a KRAS
Poole A; Karuppiah V; Hartt A; Haidar JN; Moureau S; Dobrzycki T; Hayes C; Rowley C; Dias J; Harper S; Barnbrook K; Hock M; Coles C; Yang W; Aleksic M; Lin AB; Robinson R; Dukes JD; Liddy N; Van der Kamp M; Plowman GD; Vuidepot A; Cole DK; Whale AD; Chillakuri C
Nat Commun; 2022 Sep; 13(1):5333. PubMed ID: 36088370
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
[TBL] [Abstract][Full Text] [Related]
17. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors.
Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation-induced EndMT of brain arteriovenous malformation is mediated through the TGF-β/BMP-SMAD4 pathway.
Xu H; Huo R; Li H; Jiao Y; Weng J; Wang J; Yan Z; Zhang J; Zhao S; He Q; Sun Y; Wang S; Cao Y
Stroke Vasc Neurol; 2023 Jun; 8(3):197-206. PubMed ID: 36418055
[TBL] [Abstract][Full Text] [Related]
19. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
20. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
